On the public citation graph
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
0 signed · 847 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/9781118853771.ch51openalex-snapshot
WHO Classification: Tumours of the Haematopoietic and Lymphoid Tissues (2008)
inferredcites →https://doi.org/10.1002/cncr.20288openalex-snapshot
Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival
inferredcites →https://doi.org/10.1002/cncr.27391openalex-snapshot
Identification of anaplastic lymphoma kinase fusions in renal cancer
inferredcites →https://doi.org/10.1002/cncr.27450openalex-snapshot
Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
inferredcites →https://doi.org/10.1002/cncr.27913openalex-snapshot
Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer
inferredcites →https://doi.org/10.1002/cne.20887openalex-snapshot
Anaplastic lymphoma kinase is dynamically expressed on subsets of motor neurons and in the peripheral nervous system
inferredcites →https://doi.org/10.1002/dneu.22056openalex-snapshot
Jelly belly trans‐synaptic signaling to anaplastic lymphoma kinase regulates neurotransmission strength and synapse architecture
inferredcites →https://doi.org/10.1002/gcc.10033openalex-snapshot
Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large‐cell lymphoma and inflammatory myofibroblastic tumor
inferredcites →https://doi.org/10.1002/gcc.10177openalex-snapshot
Fusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor
inferredcites →https://doi.org/10.1002/gcc.10232openalex-snapshot
Non‐muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma
inferredcites →https://doi.org/10.1002/gcc.10267openalex-snapshot
ALK‐ATIC fusion in urinary bladder inflammatory myofibroblastic tumor
inferredcites →https://doi.org/10.1002/gcc.20496openalex-snapshot
ArrayCGH‐based classification of neuroblastoma into genomic subgroups
inferredcites →https://doi.org/10.1002/gcc.21945openalex-snapshot
Discovery of ALK ‐ PTPN3 gene fusion from human non‐small cell lung carcinoma cell line using next generation RNA sequencing
inferredcites →https://doi.org/10.1002/hon.841openalex-snapshot
ALK‐positive diffuse large B‐cell lymphoma: report of three cases
inferredcites →https://doi.org/10.1002/ijc.10435openalex-snapshot
Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines
inferredcites →https://doi.org/10.1002/ijc.21490openalex-snapshot
Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor
inferredcites →https://doi.org/10.1002/mc.21836openalex-snapshot
Assessment of the transforming potential of novel anaplastic lymphoma kinase point mutants
inferredcites →https://doi.org/10.1002/path.4209openalex-snapshot
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing
inferredcites →https://doi.org/10.1002/pbc.20294openalex-snapshot
Pediatric inflammatory myofibroblastic tumor: Anaplastic lymphoma kinase (ALK) expression and prognosis
inferredcites →https://doi.org/10.1002/pmic.200500647openalex-snapshot
Proteomic analysis of anaplastic lymphoma cell lines: Identification of potential tumour markers
inferredcites →https://doi.org/10.1007/s00109-007-0159-4openalex-snapshot
Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma
inferredcites →https://doi.org/10.1007/s12264-007-0003-4openalex-snapshot
Involvement of genes required for synaptic function in aging control in C. elegans
inferredcites →https://doi.org/10.1016/j.ajpath.2011.03.045openalex-snapshot
Fusion Tyrosine Kinase NPM-ALK Deregulates MSH2 and Suppresses DNA Mismatch Repair Function
inferredcites →https://doi.org/10.1016/j.ajpath.2012.01.008openalex-snapshot
MicroRNA 96 Is a Post-Transcriptional Suppressor of Anaplastic Lymphoma Kinase Expression
inferredcites →https://doi.org/10.1016/j.bbapap.2009.10.017openalex-snapshot
Defining the conserved internal architecture of a protein kinase
inferredcites →https://doi.org/10.1016/j.bbrc.2006.10.117openalex-snapshot
The bHLH transcription factor Hand is regulated by Alk in the Drosophila embryonic gut
inferredcites →https://doi.org/10.1016/j.cancergencyto.2007.04.004openalex-snapshot
RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors
inferredcites →https://doi.org/10.1016/j.ccr.2012.02.010openalex-snapshot
Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
inferredcites →https://doi.org/10.1016/j.ccr.2012.03.004openalex-snapshot
ALK and MYCN: When Two Oncogenes Are Better than One
inferredcites →https://doi.org/10.1016/j.ccr.2012.06.001openalex-snapshot
The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
inferredcites →https://doi.org/10.1016/j.cell.2005.04.034openalex-snapshot
NIPA Defines an SCF-Type Mammalian E3 Ligase that Regulates Mitotic Entry
inferredcites →https://doi.org/10.1016/j.cell.2007.02.024openalex-snapshot
Anterograde Jelly belly and Alk Receptor Tyrosine Kinase Signaling Mediates Retinal Axon Targeting in Drosophila
inferredcites →https://doi.org/10.1016/j.cell.2007.11.025openalex-snapshot
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
inferredcites →https://doi.org/10.1016/j.cell.2009.12.040openalex-snapshot
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
inferredcites →https://doi.org/10.1016/j.cell.2010.06.004openalex-snapshot
NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome
inferredcites →https://doi.org/10.1016/j.cell.2010.06.011openalex-snapshot
Cell Signaling by Receptor Tyrosine Kinases
inferredcites →https://doi.org/10.1016/j.cell.2011.06.040openalex-snapshot
Anaplastic Lymphoma Kinase Spares Organ Growth during Nutrient Restriction in Drosophila
inferredcites →https://doi.org/10.1016/j.cellsig.2007.07.011openalex-snapshot
In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?
inferredcites →https://doi.org/10.1016/j.cub.2008.06.060openalex-snapshot
C. elegans Anaplastic Lymphoma Kinase Ortholog SCD-2 Controls Dauer Formation by Modulating TGF-β Signaling
inferredcites →https://doi.org/10.1016/j.exphem.2007.04.011openalex-snapshot
Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma
inferredcites →https://doi.org/10.1016/j.gde.2010.10.012openalex-snapshot
Protein kinase signaling networks in cancer
inferredcites →https://doi.org/10.1016/j.humpath.2006.12.019openalex-snapshot
Anaplastic lymphoma kinase–positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3′ ALK gene insertion to chromosome 4 q22-24
inferredcites →https://doi.org/10.1016/j.humpath.2008.06.009openalex-snapshot
Hyperactivated STAT3 in ALK–positive diffuse large B-cell lymphoma with clathrin-ALK fusion
inferredcites →https://doi.org/10.1016/j.modgep.2005.11.006openalex-snapshot
Characterization of the expression of the ALK receptor tyrosine kinase in mice
inferredcites →https://doi.org/10.1016/j.molcel.2008.12.024openalex-snapshot
A Conserved Salt Bridge in the G Loop of Multiple Protein Kinases Is Important for Catalysis and for In Vivo Lyn Function
inferredcites →https://doi.org/10.1016/j.pbb.2011.10.024openalex-snapshot
Anaplastic Lymphoma Kinase and Leukocyte Tyrosine Kinase: Functions and genetic interactions in learning, memory and adult neurogenesis
inferredcites →https://doi.org/10.1016/s0002-9440(10)61711-7openalex-snapshot
Fusion of the ALK Gene to the Clathrin Heavy Chain Gene, CLTC, in Inflammatory Myofibroblastic Tumor
inferredcites →https://doi.org/10.1016/s0002-9440(10)62574-6openalex-snapshot
Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas
inferredcites →https://doi.org/10.1016/s0002-9440(10)64550-6openalex-snapshot
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
inferredcites →https://doi.org/10.1016/s0002-9440(10)64945-0openalex-snapshot
ATIC-ALK: A Novel Variant ALK Gene Fusion in Anaplastic Large Cell Lymphoma Resulting from the Recurrent Cryptic Chromosomal Inversion, inv(2)(p23q35)
inferredcites →https://doi.org/10.1016/s0002-9440(10)65042-0openalex-snapshot
Expression of the ALK Tyrosine Kinase Gene in Neuroblastoma
inferredcites →https://doi.org/10.1016/s0092-8674(02)00748-1openalex-snapshot
HEN-1, a Secretory Protein with an LDL Receptor Motif, Regulates Sensory Integration and Learning in Caenorhabditis elegans
inferredcites →https://doi.org/10.1016/s0092-8674(03)00190-9openalex-snapshot
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
inferredcites →https://doi.org/10.1016/s0304-3835(03)00450-6openalex-snapshot
Midkine and pleiotrophin in neural development and cancer
inferredcites →https://doi.org/10.1016/s1470-2045(13)70095-0openalex-snapshot
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
inferredcites →https://doi.org/10.1016/s1470-2045(13)70142-6openalex-snapshot
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
inferredcites →https://doi.org/10.1021/bi1005514openalex-snapshot
Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors
inferredcites →https://doi.org/10.1021/cb300361aopenalex-snapshot
A Simple, Highly Visual in Vivo Screen for Anaplastic Lymphoma Kinase Inhibitors
inferredcites →https://doi.org/10.1021/jm0603116openalex-snapshot
Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90
inferredcites →https://doi.org/10.1038/ejhg.2011.195openalex-snapshot
ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome
inferredcites →https://doi.org/10.1038/labinvest.3780249openalex-snapshot
Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma
inferredcites →https://doi.org/10.1038/leu.2011.168openalex-snapshot
Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas
inferredcites →https://doi.org/10.1038/modpathol.2010.213openalex-snapshot
Renal cell carcinoma with novel VCL–ALK fusion: new representative of ALK-associated tumor spectrum
inferredcites →https://doi.org/10.1038/modpathol.2012.107openalex-snapshot
ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients
inferredcites →https://doi.org/10.1038/modpathol.3800742openalex-snapshot
ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature
inferredcites →https://doi.org/10.1038/nature01916openalex-snapshot
Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers
inferredcites →https://doi.org/10.1038/nature01950openalex-snapshot
Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion
inferredcites →https://doi.org/10.1038/nature02647openalex-snapshot
An SCF-like ubiquitin ligase complex that controls presynaptic differentiation
inferredcites →https://doi.org/10.1038/nature05945openalex-snapshot
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
inferredcites →https://doi.org/10.1038/nature07261openalex-snapshot
Identification of ALK as a major familial neuroblastoma predisposition gene
inferredcites →https://doi.org/10.1038/nature07310openalex-snapshot
E2F1 represses β-catenin transcription and is antagonized by both pRB and CDK8
inferredcites →https://doi.org/10.1038/nature07397openalex-snapshot
Activating mutations in ALK provide a therapeutic target in neuroblastoma
inferredcites →https://doi.org/10.1038/nature07398openalex-snapshot
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
inferredcites →https://doi.org/10.1038/nature07399openalex-snapshot
Oncogenic mutations of ALK kinase in neuroblastoma
inferredcites →https://doi.org/10.1038/nbt.2284openalex-snapshot
Combinatorial drug therapy for cancer in the post-genomic era
inferredcites →https://doi.org/10.1038/nbt1046openalex-snapshot
Immunoaffinity profiling of tyrosine phosphorylation in cancer cells
inferredcites →https://doi.org/10.1038/ng.2529openalex-snapshot
The genetic landscape of high-risk neuroblastoma
inferredcites →https://doi.org/10.1038/nm.2673openalex-snapshot
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
inferredcites →https://doi.org/10.1038/nm1087openalex-snapshot
Cancer genes and the pathways they control
inferredcites →https://doi.org/10.1038/nm1769openalex-snapshot
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
inferredcites →https://doi.org/10.1038/nrc1165openalex-snapshot
The significance of unstable chromosomes in colorectal cancer
inferredcites →https://doi.org/10.1038/nrc2291openalex-snapshot
The anaplastic lymphoma kinase in the pathogenesis of cancer
inferredcites →https://doi.org/10.1038/nrclinonc.2012.72openalex-snapshot
Targeting ALK in neuroblastoma—preclinical and clinical advancements
inferredcites →https://doi.org/10.1038/onc.2009.512openalex-snapshot
Myc proteins as therapeutic targets
inferredcites →https://doi.org/10.1038/onc.2010.505openalex-snapshot
Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA
inferredcites →https://doi.org/10.1038/onc.2010.625openalex-snapshot
The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
inferredcites →https://doi.org/10.1038/onc.2011.616openalex-snapshot
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma
inferredcites →https://doi.org/10.1038/onc.2011.647openalex-snapshot
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma
inferredcites →https://doi.org/10.1038/onc.2012.12openalex-snapshot
Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells
inferredcites →https://doi.org/10.1038/sj.embor.embor897openalex-snapshot
A crucial role for the Anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster
inferredcites →https://doi.org/10.1038/sj.npp.1301446openalex-snapshot
Behavioral and Neurochemical Alterations in Mice Deficient in Anaplastic Lymphoma Kinase Suggest Therapeutic Potential for Psychiatric Indications
inferredcites →https://doi.org/10.1038/sj.onc.1200849openalex-snapshot
Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system
inferredcites →https://doi.org/10.1038/sj.onc.1201062openalex-snapshot
ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
inferredcites →https://doi.org/10.1038/sj.onc.1202171openalex-snapshot
Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis
inferredcites →https://doi.org/10.1038/sj.onc.1205735openalex-snapshot
Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines
inferredcites →https://doi.org/10.1038/sj.onc.1207398openalex-snapshot
Identification of NPM-ALK interacting proteins by tandem mass spectrometry
inferredcites →https://doi.org/10.1038/sj.onc.1207813openalex-snapshot
Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells
inferredcites →https://doi.org/10.1038/sj.onc.1208523openalex-snapshot
Domain-specific function of ShcC docking protein in neuroblastoma cells
inferredcites →https://doi.org/10.1038/sj.onc.1210921openalex-snapshot
Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas
inferredcites →https://doi.org/10.1042/bj20081834openalex-snapshot
High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours
inferredcites →https://doi.org/10.1042/bj20090387openalex-snapshot
Anaplastic lymphoma kinase: signalling in development and disease
inferredcites →https://doi.org/10.1042/bj20100609openalex-snapshot
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
inferredcites →https://doi.org/10.1042/bj20101796openalex-snapshot
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684
inferredcites →https://doi.org/10.1046/j.1365-2443.2001.00440.xopenalex-snapshot
Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo
inferredcites →https://doi.org/10.1056/nejmct0807960openalex-snapshot
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
inferredcites →https://doi.org/10.1056/nejme1010404openalex-snapshot
Crizotinib — Latest Champion in the Cancer Wars?
inferredcites →https://doi.org/10.1056/nejmoa1006448openalex-snapshot
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1007478openalex-snapshot
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
inferredcites →https://doi.org/10.1056/nejmoa1214886openalex-snapshot
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
inferredcites →https://doi.org/10.1056/nejmra0804577openalex-snapshot
Recent Advances in Neuroblastoma
inferredcites →https://doi.org/10.1073/pnas.0608372103openalex-snapshot
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90
inferredcites →https://doi.org/10.1073/pnas.0709662105openalex-snapshot
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
inferredcites →https://doi.org/10.1074/jbc.m010660200openalex-snapshot
Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin
inferredcites →https://doi.org/10.1074/jbc.m110.121988openalex-snapshot
The Tyrosine 343 Residue of Nucleophosmin (NPM)-Anaplastic Lymphoma Kinase (ALK) Is Important for Its Interaction with SHP1, a Cytoplasmic Tyrosine Phosphatase with Tumor Suppressor Functions
inferredcites →https://doi.org/10.1074/jbc.m111.227512openalex-snapshot
The Nucleophosmin-Anaplastic Lymphoma Kinase Oncogene Interacts, Activates, and Uses the Kinase PIKfyve to Increase Invasiveness
inferredcites →https://doi.org/10.1074/jbc.m112.391425openalex-snapshot
The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase
inferredcites →https://doi.org/10.1074/jbc.m205749200openalex-snapshot
Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types
inferredcites →https://doi.org/10.1074/jbc.m300883200openalex-snapshot
Identification and Characterization of a Nuclear Interacting Partner of Anaplastic Lymphoma Kinase (NIPA)
inferredcites →https://doi.org/10.1074/jbc.m501972200openalex-snapshot
Activation and Inhibition of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase by Monoclonal Antibodies and Absence of Agonist Activity of Pleiotrophin
inferredcites →https://doi.org/10.1074/jbc.m704505200openalex-snapshot
Anaplastic Lymphoma Kinase Is Activated Through the Pleiotrophin/Receptor Protein-tyrosine Phosphatase β/ζ Signaling Pathway
inferredcites →https://doi.org/10.1074/jbc.m706067200openalex-snapshot
Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase
inferredcites →https://doi.org/10.1093/genetics/156.3.1035openalex-snapshot
Suppressors of Transforming Growth Factor-β Pathway Mutants in the Caenorhabditis elegans Dauer Formation Pathway
inferredcites →https://doi.org/10.1093/oxfordjournals.jbchem.a003231openalex-snapshot
Midkine and Pleiotrophin: Two Related Proteins Involved in Development, Survival, Inflammation and Tumorigenesis
inferredcites →https://doi.org/10.1097/00000478-200311000-00012openalex-snapshot
A Case of a Diffuse Large B-Cell Lymphoma of Plasmablastic Type Associated With the t(2;5)(p23;q35) Chromosome Translocation
inferredcites →https://doi.org/10.1097/01.lab.0000088856.49388.eaopenalex-snapshot
Identification of CARS-ALK Fusion in Primary and Metastatic Lesions of an Inflammatory Myofibroblastic Tumor
inferredcites →https://doi.org/10.1097/01.mp.0000026615.04130.1fopenalex-snapshot
Expression of ALK1 and p80 in Inflammatory Myofibroblastic Tumor and Its Mesenchymal Mimics: A Study of 135 Cases
inferredcites →https://doi.org/10.1097/jto.0b013e3181fb7cd6openalex-snapshot
Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer
inferredcites →https://doi.org/10.1097/jto.0b013e318200f9ffopenalex-snapshot
Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer
inferredcites →https://doi.org/10.1101/gad.1479906openalex-snapshot
Insulin-like signaling and the neural circuit for integrative behavior in C. elegans
inferredcites →https://doi.org/10.1111/j.1432-0436.2006.00148.xopenalex-snapshot
Drosophila Anaplastic Lymphoma Kinase regulates Dpp signalling in the developing embryonic gut
inferredcites →https://doi.org/10.1111/j.1460-9568.2008.06593.xopenalex-snapshot
ALK (Anaplastic Lymphoma Kinase) expression in DRG neurons and its involvement in neuron–Schwann cells interaction
inferredcites →https://doi.org/10.1126/science.8122112openalex-snapshot
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
inferredcites →https://doi.org/10.1126/scitranslmed.3002950openalex-snapshot
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
inferredcites →https://doi.org/10.1126/scitranslmed.3003316openalex-snapshot
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
inferredcites →https://doi.org/10.1126/scitranslmed.3003967openalex-snapshot
Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice
inferredcites →https://doi.org/10.1128/mcb.01515-05openalex-snapshot
Anaplastic Lymphoma Kinase Is a Dependence Receptor Whose Proapoptotic Functions Are Activated by Caspase Cleavage
inferredcites →https://doi.org/10.1158/0008-5472.can-05-2769openalex-snapshot
Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma
inferredcites →https://doi.org/10.1158/0008-5472.can-06-4350openalex-snapshot
The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration
inferredcites →https://doi.org/10.1158/0008-5472.can-08-2568openalex-snapshot
The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation
inferredcites →https://doi.org/10.1158/0008-5472.can-08-4419openalex-snapshot
Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients
inferredcites →https://doi.org/10.1158/0008-5472.can-10-2366openalex-snapshot
Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
inferredcites →https://doi.org/10.1158/0008-5472.can-10-2956openalex-snapshot
The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
inferredcites →https://doi.org/10.1158/0008-5472.can-10-4041openalex-snapshot
Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
inferredcites →https://doi.org/10.1158/0008-5472.can-11-1340openalex-snapshot
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
inferredcites →https://doi.org/10.1158/0008-5472.can-11-3931openalex-snapshot
Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer
inferredcites →https://doi.org/10.1158/0008-5472.can-12-1242openalex-snapshot
Characterization of Rearrangements Involving the ALK Gene Reveals a Novel Truncated Form Associated with Tumor Aggressiveness in Neuroblastoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-2762openalex-snapshot
Inhibition of ALK Signaling for Cancer Therapy
inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-3248openalex-snapshot
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-2660openalex-snapshot
Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
inferredcites →https://doi.org/10.1158/1078-0432.ccr-10-2809openalex-snapshot
High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-0063openalex-snapshot
Pulmonary Inflammatory Myofibroblastic Tumor Expressing a Novel Fusion, PPFIBP1–ALK: Reappraisal of Anti-ALK Immunohistochemistry as a Tool for Novel ALK Fusion Identification
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-1648openalex-snapshot
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-2906openalex-snapshot
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1158/1535-7163.mct-07-0365openalex-snapshot
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
inferredcites →https://doi.org/10.1158/1535-7163.mct-11-0692openalex-snapshot
Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling
inferredcites →https://doi.org/10.1158/1538-7445.am2011-4403openalex-snapshot
Abstract 4403: Differential cytotoxic effects of atorvastatin in human hepatocellular carcinoma and pancreatic adenocarcinoma cells
inferredcites →https://doi.org/10.1158/1541-7786.mcr-08-0522openalex-snapshot
Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers
inferredcites →https://doi.org/10.1172/jci29401openalex-snapshot
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes
inferredcites →https://doi.org/10.1177/1947601911416003openalex-snapshot
Cooperative Cross-Talk between Neuroblastoma Subtypes Confers Resistance to Anaplastic Lymphoma Kinase Inhibition
inferredcites →https://doi.org/10.1182/blood-2003-04-1038openalex-snapshot
Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity
inferredcites →https://doi.org/10.1182/blood-2003-04-1050openalex-snapshot
ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma
inferredcites →https://doi.org/10.1182/blood-2003-04-1095openalex-snapshot
ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases
inferredcites →https://doi.org/10.1182/blood-2005-03-1204openalex-snapshot
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase
inferredcites →https://doi.org/10.1182/blood-2006-01-028647openalex-snapshot
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma
inferredcites →https://doi.org/10.1182/blood-2007-02-071258openalex-snapshot
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling
inferredcites →https://doi.org/10.1182/blood-2007-04-060715openalex-snapshot
Pathobiology of ALK+ anaplastic large-cell lymphoma
inferredcites →https://doi.org/10.1182/blood-2008-01-134270openalex-snapshot
ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
inferredcites →https://doi.org/10.1182/blood-2008-06-161018openalex-snapshot
The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL
inferredcites →https://doi.org/10.1182/blood-2009-02-204735openalex-snapshot
The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways
inferredcites →https://doi.org/10.1182/blood-2010-09-301994openalex-snapshot
MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression
inferredcites →https://doi.org/10.1182/blood-2011-05-354654openalex-snapshot
miR-135b mediates NPM-ALK–driven oncogenicity and renders IL-17–producing immunophenotype to anaplastic large cell lymphoma
inferredcites →https://doi.org/10.1182/blood.v86.5.1954.bloodjournal8651954openalex-snapshot
Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity
inferredcites →https://doi.org/10.1182/blood.v89.4.1394openalex-snapshot
Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM)-ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1
inferredcites →https://doi.org/10.1182/blood.v93.11.3913openalex-snapshot
Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma
inferredcites →https://doi.org/10.1182/blood.v93.8.2697openalex-snapshot
ALK+ lymphoma: clinico-pathological findings and outcome.
inferredcites →https://doi.org/10.1182/blood.v93.9.3088openalex-snapshot
A New Fusion Gene TPM3-ALK in Anaplastic Large Cell Lymphoma Created by a (1;2)(q25;p23) Translocation
inferredcites →https://doi.org/10.1182/blood.v94.10.3614.422a38e_3614_3617openalex-snapshot
Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma.
inferredcites →https://doi.org/10.1182/blood.v94.9.3265openalex-snapshot
TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally DifferentTFG-ALK Translocations
inferredcites →https://doi.org/10.1182/blood.v95.10.3204openalex-snapshot
Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)
inferredcites →https://doi.org/10.1182/blood.v95.6.2144openalex-snapshot
Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis
inferredcites →https://doi.org/10.1182/blood.v96.12.3681openalex-snapshot
CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features
inferredcites →https://doi.org/10.1182/blood.v98.4.1209openalex-snapshot
Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4–anaplastic lymphoma kinase gene fusion
inferredcites →https://doi.org/10.1200/jco.2005.06.104openalex-snapshot
Unequivocal Delineation of Clinicogenetic Subgroups and Development of a New Model for Improved Outcome Prediction in Neuroblastoma
inferredcites →https://doi.org/10.1200/jco.2008.16.0630openalex-snapshot
Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma
inferredcites →https://doi.org/10.1200/jco.2009.22.6993openalex-snapshot
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
inferredcites →https://doi.org/10.1200/jco.2010.30.8338openalex-snapshot
Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2011.29.15_suppl.2501openalex-snapshot
Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
inferredcites →https://doi.org/10.1200/jco.2011.29.15_suppl.7507openalex-snapshot
Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls.
inferredcites →https://doi.org/10.1200/jco.2011.29.15_suppl.cra7506openalex-snapshot
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).
inferredcites →https://doi.org/10.1200/jco.2011.29.18_suppl.cra7506openalex-snapshot
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).
inferredcites →https://doi.org/10.1242/dev.00972openalex-snapshot
Myoblast determination in the somatic and visceral mesoderm depends on Notch signalling as well as onmilliways(miliAlk) as receptor for Jeb signalling
inferredcites →https://doi.org/10.1242/dev.047878openalex-snapshot
Anterograde Jelly belly ligand to Alk receptor signaling at developing synapses is regulated by Mind the gap
inferredcites →https://doi.org/10.1242/dev.123.1.369openalex-snapshot
Zebrafish pigmentation mutations and the processes of neural crest development
inferredcites →https://doi.org/10.1242/dmm.010348openalex-snapshot
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma
inferredcites →https://doi.org/10.1242/jcs.01183openalex-snapshot
ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth
inferredcites →https://doi.org/10.1242/jeb.006551openalex-snapshot
Temperature and food mediate long-term thermotactic behavioral plasticity by association-independent mechanisms in C. elegans
inferredcites →https://doi.org/10.1371/journal.pgen.1000026openalex-snapshot
Leukocyte Tyrosine Kinase Functions in Pigment Cell Development
inferredcites →https://doi.org/10.1371/journal.pgen.1002281openalex-snapshot
The Receptor Tyrosine Kinase Alk Controls Neurofibromin Functions in Drosophila Growth and Learning
showing the first 200 of 217 · page through all 217
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4834038openalex-extracted
Molecular Subtypes of Amino Acid Metabolism-Related Genes Predicting Prognosis, Tumor Microenvironment Composition, and Therapeutic Response in Neuroblastoma
inferred← citeshttps://doi.org/10.2139/ssrn.4856228openalex-extracted
Drug-Induced Liver Injury Associated with Alk Inhibitors: A Pharmacovigilance Analysis of the Fda Adverse Event Reporting System (Faers)
inferred← citeshttps://doi.org/10.1002/1878-0261.12822openalex-snapshot
EBP2, a novel NPM‐ALK‐interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53
inferred← citeshttps://doi.org/10.1002/9781118681121.ch16openalex-snapshot
The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm010openalex-snapshot
Aberrant Signaling Pathways in Cancer
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm010.pub2openalex-snapshot
Aberrant Signaling Pathways in Cancer
inferred← citeshttps://doi.org/10.1002/adtp.202000148openalex-snapshot
PROteolysis TArgetting Chimeras (PROTACs) Strategy Applied to Kinases: Recent Advances
inferred← citeshttps://doi.org/10.1002/ajh.25043openalex-snapshot
Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study
inferred← citeshttps://doi.org/10.1002/bkcs.10454openalex-snapshot
Design, Synthesis, and Evaluation of 2‐Anilino‐4‐(3,5‐dicarboxamidespiperidine)‐pyrimidines as Anaplastic Lymphoma Kinase Inhibitors
inferred← citeshttps://doi.org/10.1002/cjp2.64openalex-snapshot
Fluorescence in situ hybridization in surgical pathology: principles and applications
inferred← citeshttps://doi.org/10.1002/cncr.35293openalex-snapshot
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer
inferred← citeshttps://doi.org/10.1002/cnr2.1166openalex-snapshot
Development and validation of an immune prognostic signature for ovarian carcinoma
inferred← citeshttps://doi.org/10.1002/cnr2.70489openalex-snapshot
A Giant Thoracic ALK ‐Rearranged Mesenchymal Neoplasm in a Child
inferred← citeshttps://doi.org/10.1002/ctm2.1732openalex-snapshot
Impact of ALK inhibitors to potentiate ALK.CAR‐T therapy in neuroblastoma
inferred← citeshttps://doi.org/10.1002/gcc.22223openalex-snapshot
Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism of ALK activation in neuroblastoma tumors
inferred← citeshttps://doi.org/10.1002/gcc.22790openalex-snapshot
Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements
inferred← citeshttps://doi.org/10.1002/gcc.22917openalex-snapshot
Spindle cell neoplasm with EML4‐ALK gene fusion presenting as an intraosseous vertebral mass
inferred← citeshttps://doi.org/10.1002/gcc.23093openalex-snapshot
Loss of ALK hotspot mutations in relapsed neuroblastoma
inferred← citeshttps://doi.org/10.1002/gcc.23097openalex-snapshot
ALK‐rearranged Mesenchymal Neoplasms: A Report of 9 cases Further Expanding the Clinicopathologic Spectrum of Emerging Kinase Fusion Positive Group of Tumors
inferred← citeshttps://doi.org/10.1002/gcc.23207openalex-snapshot
A cutaneous epithelioid vascular tumor harboring a TPM3::ALK fusion
inferred← citeshttps://doi.org/10.1002/jha2.1071openalex-snapshot
Myeloproliferative neoplasm harboring both monosomy 7 and an ALK/ROS1 fusion gene: Proposal for a new disease entity
inferred← citeshttps://doi.org/10.1002/mog2.50openalex-snapshot
Applications of macrocyclic molecules in cancer therapy: Target cancer development or overcome drug resistance
inferred← citeshttps://doi.org/10.1002/path.5038openalex-snapshot
Established, emerging and elusive molecular targets in the treatment of lung cancer
inferred← citeshttps://doi.org/10.1002/pbc.25424openalex-snapshot
FN1: A novel fusion partner of ALK in an inflammatory myofibroblastic tumor
inferred← citeshttps://doi.org/10.1002/pbc.26920openalex-snapshot
Crizotinib in ALK+ inflammatory myofibroblastic tumors—Current experience and future perspectives
inferred← citeshttps://doi.org/10.1002/pbc.30516openalex-snapshot
EML4::ALK fusions in complex lymphatic malformations
inferred← citeshttps://doi.org/10.1002/rcr2.984openalex-snapshot
Endotracheal inflammatory myofibroblastic tumour: A rare cause of central airway occlusion in adults
inferred← citeshttps://doi.org/10.1002/rmb2.12221openalex-snapshot
Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis
inferred← citeshttps://doi.org/10.1007/7355_2020_100openalex-snapshot
Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook
inferred← citeshttps://doi.org/10.1007/978-1-4939-1607-8_8openalex-snapshot
New Discoveries for the Treatment of Lung Cancer and the Role of Small Biopsy Material
inferred← citeshttps://doi.org/10.1007/978-3-030-17832-1_2openalex-snapshot
Anaplastic Lymphoma Kinase
inferred← citeshttps://doi.org/10.1007/978-3-030-73227-1_18openalex-snapshot
Mature T- and NK-Cell Neoplasms
inferred← citeshttps://doi.org/10.1007/978-3-319-14340-8_1openalex-snapshot
Growth Factors and Tyrosine Kinase Receptors
inferred← citeshttps://doi.org/10.1007/978-3-319-46038-3_5openalex-snapshot
Molecular Genetics of Neuroblastoma
inferred← citeshttps://doi.org/10.1007/978-3-319-62941-4_10openalex-snapshot
Next-Generation and Third-Generation Sequencing of Lung Cancer Biomarkers
inferred← citeshttps://doi.org/10.1007/978-3-319-63757-0_9openalex-snapshot
Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-3-662-43686-8_12openalex-snapshot
Molekular zielgerichtete Therapien
inferred← citeshttps://doi.org/10.1007/978-981-13-5877-7_7openalex-snapshot
Molecular Diagnostics in Non-Hodgkin Lymphoma
inferred← citeshttps://doi.org/10.1007/s00018-015-2117-6openalex-snapshot
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
inferred← citeshttps://doi.org/10.1007/s00109-014-1165-yopenalex-snapshot
Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
inferred← citeshttps://doi.org/10.1007/s00280-026-04910-zopenalex-snapshot
ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications
inferred← citeshttps://doi.org/10.1007/s00381-023-05925-0openalex-snapshot
Inflammatory myofibroblastic tumor of the lung involving the central nervous system in pediatric patients
inferred← citeshttps://doi.org/10.1007/s00428-025-04198-zopenalex-snapshot
ALK rearranged malignant mesenchymal neoplasms of thorax: therapeutically targetable ‘ALKomas’ beyond the spectrum of non-small cell lung carcinomas and thoracic inflammatory myofibroblastic tumors
inferred← citeshttps://doi.org/10.1007/s00428-025-04208-0openalex-snapshot
Small bowel metastatic SWI/SNF-deficient undifferentiated carcinoma may be predictive of lung primary—a rare presentation with novel SMARCA2 mutation findings in a study of three cases
inferred← citeshttps://doi.org/10.1007/s00428-026-04565-4openalex-snapshot
Renal cell carcinoma with a novel RAB1A::ALK fusion: expanding the molecular spectrum of ALK-rearranged RCC
inferred← citeshttps://doi.org/10.1007/s00441-017-2784-8openalex-snapshot
The ALK receptor in sympathetic neuron development and neuroblastoma
inferred← citeshttps://doi.org/10.1007/s00441-018-2820-3openalex-snapshot
Genetic susceptibility to neuroblastoma: current knowledge and future directions
inferred← citeshttps://doi.org/10.1007/s10555-016-9649-6openalex-snapshot
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
inferred← citeshttps://doi.org/10.1007/s10555-026-10364-9openalex-snapshot
Three decades of anaplastic lymphoma kinase: from physiological roles to cancer and immune evasion
inferred← citeshttps://doi.org/10.1007/s10637-023-01350-xopenalex-snapshot
Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s11030-024-10990-xopenalex-snapshot
Classification models and SAR analysis of anaplastic lymphoma kinase (ALK) inhibitors using machine learning algorithms with two data division methods
inferred← citeshttps://doi.org/10.1007/s11033-026-12833-4openalex-snapshot
ALK ATI in solid tumours: biological evidence, diagnostic challenges, and clinical relevance, a narrative review
inferred← citeshttps://doi.org/10.1007/s11060-019-03348-zopenalex-snapshot
cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma
inferred← citeshttps://doi.org/10.1007/s11239-023-02916-5openalex-snapshot
EML4-ALK fusion protein in Lung cancer cells enhances venous thrombogenicity through the pERK1/2-AP-1-tissue factor axis
inferred← citeshttps://doi.org/10.1007/s11427-019-9506-xopenalex-snapshot
ALK-mediated Tyr95 phosphorylation of Smad4 impairs its transcription activity and the tumor suppressive activity of TGF-β
inferred← citeshttps://doi.org/10.1007/s11864-017-0513-xopenalex-snapshot
Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS
inferred← citeshttps://doi.org/10.1007/s11864-019-0675-9openalex-snapshot
Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC
inferred← citeshttps://doi.org/10.1007/s11912-025-01650-wopenalex-snapshot
15 Years Old ALK Gene from Birth to Adolescence; Where to in NBL
inferred← citeshttps://doi.org/10.1007/s12032-018-1133-4openalex-snapshot
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
inferred← citeshttps://doi.org/10.1007/s12253-016-0144-8openalex-snapshot
Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets
inferred← citeshttps://doi.org/10.1007/s12253-017-0332-1openalex-snapshot
The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors
inferred← citeshttps://doi.org/10.1007/s12272-013-0323-zopenalex-snapshot
ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment
inferred← citeshttps://doi.org/10.1007/s13258-024-01614-7openalex-snapshot
Advances in cancer genomics and precision oncology
inferred← citeshttps://doi.org/10.1007/s40265-015-0415-9openalex-snapshot
Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions
inferred← citeshttps://doi.org/10.1007/s40265-020-01445-2openalex-snapshot
Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/s40291-019-00389-yopenalex-snapshot
Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis
inferred← citeshttps://doi.org/10.1007/s40656-017-0135-4openalex-snapshot
Informing materials: drugs as tools for exploring cancer mechanisms and pathways
inferred← citeshttps://doi.org/10.1007/s42399-022-01155-8openalex-snapshot
Inflammatory Myofibroblastic Tumor in the Inguinal Canal: a Rare Case Report and a Literature Review
inferred← citeshttps://doi.org/10.1016/b978-0-12-394447-4.30001-3openalex-snapshot
Receptor Tyrosine Kinases and Their Ligands
inferred← citeshttps://doi.org/10.1016/b978-0-12-801238-3.11701-5openalex-snapshot
Molecular Targetable Pathways—ALK
inferred← citeshttps://doi.org/10.1016/b978-0-12-811785-9.00031-4openalex-snapshot
Gene Fusion in NSCLC
inferred← citeshttps://doi.org/10.1016/b978-0-12-821618-7.00226-1openalex-snapshot
Receptor Tyrosine Kinases and Their Ligands
inferred← citeshttps://doi.org/10.1016/b978-0-12-821774-0.00010-3openalex-snapshot
The ALK receptor tyrosine kinase journey: From physiological roles to pathological disruptions
inferred← citeshttps://doi.org/10.1016/b978-0-323-37678-5.50039-6openalex-snapshot
ALK Gene Rearrangements and Mutations
inferred← citeshttps://doi.org/10.1016/b978-0-323-47674-4.00002-5openalex-snapshot
Intracellular Signaling
inferred← citeshttps://doi.org/10.1016/b978-0-323-52357-8.00047-0openalex-snapshot
Pharmacogenomics in Lung Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-443-15717-2.00111-6openalex-snapshot
Role of Eukaryotic Translation Elongation Factors in the Pathogenesis of Hematological Malignancies
inferred← citeshttps://doi.org/10.1016/b978-0-443-19110-7.00008-2openalex-snapshot
Translational transcriptomics for personalized oncology
inferred← citeshttps://doi.org/10.1016/b978-0-443-43974-2.00012-4openalex-snapshot
Kinase inhibitors in diseases therapy
inferred← citeshttps://doi.org/10.1016/b978-1-4557-5414-4.00054-1openalex-snapshot
10.1016/b978-1-4557-5414-4.00054-1
inferred← citeshttps://doi.org/10.1016/j.advms.2022.02.002openalex-snapshot
What do we know about inflammatory myofibroblastic tumors? – A systematic review
inferred← citeshttps://doi.org/10.1016/j.ajpath.2015.10.016openalex-snapshot
Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma
inferred← citeshttps://doi.org/10.1016/j.ajpath.2021.06.009openalex-snapshot
Anaplastic Lymphoma Kinase Overexpression Is Associated with Aggressive Phenotypic Characteristics of Ovarian High-Grade Serous Carcinoma
inferred← citeshttps://doi.org/10.1016/j.asjsur.2023.11.152openalex-snapshot
Coexistence of a novel intergenic (between CHST2 and SLC9A9)-ALK, TNIK-ALK double-fusion in resected lung adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.bbrc.2015.07.027openalex-snapshot
Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins
inferred← citeshttps://doi.org/10.1016/j.bbrc.2016.03.053openalex-snapshot
Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells
inferred← citeshttps://doi.org/10.1016/j.bbrc.2016.12.037openalex-snapshot
Chaperone-mediated autophagy promotes lung cancer cell survival through selective stabilization of the pro-survival protein, MCL1
inferred← citeshttps://doi.org/10.1016/j.bbrc.2018.09.169openalex-snapshot
Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
inferred← citeshttps://doi.org/10.1016/j.bcp.2020.114155openalex-snapshot
SMAD-oncoprotein interplay: Potential determining factors in targeted therapies
inferred← citeshttps://doi.org/10.1016/j.bioorg.2023.106807openalex-snapshot
Synthesis and clinical application of small-molecule inhibitors and PROTACs of anaplastic lymphoma kinase
inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.107204openalex-snapshot
Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins
inferred← citeshttps://doi.org/10.1016/j.bioorg.2025.108417openalex-snapshot
Advances of dual inhibitors based on ALK for the treatment of cancer
inferred← citeshttps://doi.org/10.1016/j.bioorg.2026.109706openalex-snapshot
Rational design of dual ALK inhibitors: scaffolds and strategies to circumvent drug resistance
inferred← citeshttps://doi.org/10.1016/j.biopha.2022.114162openalex-snapshot
Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.bmcl.2016.10.039openalex-snapshot
Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core
inferred← citeshttps://doi.org/10.1016/j.bmcl.2022.128990openalex-snapshot
Fragment-based discovery of novel phenyltriazolyl derivatives as allosteric type-I1/2 ALK inhibitors with promising antitumor effects
inferred← citeshttps://doi.org/10.1016/j.cancergen.2015.01.003openalex-snapshot
Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7
inferred← citeshttps://doi.org/10.1016/j.canlet.2016.02.009openalex-snapshot
Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer
inferred← citeshttps://doi.org/10.1016/j.canlet.2016.11.008openalex-snapshot
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
inferred← citeshttps://doi.org/10.1016/j.cbi.2018.02.018openalex-snapshot
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells
inferred← citeshttps://doi.org/10.1016/j.cca.2018.07.009openalex-snapshot
Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS
inferred← citeshttps://doi.org/10.1016/j.ccell.2014.09.019openalex-snapshot
ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
inferred← citeshttps://doi.org/10.1016/j.ccell.2023.11.004openalex-snapshot
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
inferred← citeshttps://doi.org/10.1016/j.cell.2025.01.024openalex-snapshot
GUK1 activation is a metabolic liability in lung cancer
inferred← citeshttps://doi.org/10.1016/j.celrep.2021.109515openalex-snapshot
NGPF2 Triggers Synaptic Scaling Up Through ALK-LIMK-Cofilin Mediated Mechanisms
inferred← citeshttps://doi.org/10.1016/j.cllc.2026.01.004openalex-snapshot
First Frameshift Mutation of ALK in Non-Small Cell Lung Cancer Remaining Sensitive to Alectinib: Case Report
inferred← citeshttps://doi.org/10.1016/j.cllc.2026.09.002openalex-snapshot
Rapid Lorlatinib Response in Lung Adenocarcinoma With a Novel Y Chromosome Intergenic ALK Fusion: A Case Report
inferred← citeshttps://doi.org/10.1016/j.colsurfb.2025.114974openalex-snapshot
Precision targeting of ALK-positive lung cancer: Engineering HFN@MS4078 nanocages for optimized PROTAC delivery
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2019.02.006openalex-snapshot
ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2025.104870openalex-snapshot
Pathology, immunosuppression and NK cell immunotherapy of non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.ctrv.2021.102179openalex-snapshot
Immunotherapy in non-small cell lung cancer harbouring driver mutations
inferred← citeshttps://doi.org/10.1016/j.currproblcancer.2021.100774openalex-snapshot
Editorial: Special issue on rare cancers
inferred← citeshttps://doi.org/10.1016/j.drup.2024.101081openalex-snapshot
Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome
inferred← citeshttps://doi.org/10.1016/j.ebiom.2019.01.019openalex-snapshot
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
inferred← citeshttps://doi.org/10.1016/j.ejca.2021.08.022openalex-snapshot
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies
inferred← citeshttps://doi.org/10.1016/j.ejmech.2015.10.005openalex-snapshot
Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: Design, synthesis, and structure—activity relationship study
inferred← citeshttps://doi.org/10.1016/j.ejmech.2016.06.056openalex-snapshot
Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1
inferred← citeshttps://doi.org/10.1016/j.ejmech.2018.03.071openalex-snapshot
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
inferred← citeshttps://doi.org/10.1016/j.ejmech.2019.05.060openalex-snapshot
Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors
inferred← citeshttps://doi.org/10.1016/j.ejmech.2019.06.043openalex-snapshot
Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors
inferred← citeshttps://doi.org/10.1016/j.ejmech.2020.112190openalex-snapshot
Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
inferred← citeshttps://doi.org/10.1016/j.ejmech.2021.113906openalex-snapshot
VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.117722openalex-snapshot
Progression and expansion of ALK inhibitors against NSCLC: A dual target approach
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.117835openalex-snapshot
Discovery of an ALK degrader for lorlatinib-resistant compound mutations
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.118053openalex-snapshot
The past, present, and future of ALK-targeted drug discovery
inferred← citeshttps://doi.org/10.1016/j.ejphar.2015.02.029openalex-snapshot
Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.ejps.2025.107087openalex-snapshot
Development and preclinical evaluation of a gallium-68 labeled novel diagnostic tracer for visualizing ALK expression in tumor
inferred← citeshttps://doi.org/10.1016/j.esmoop.2025.105574openalex-snapshot
Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study
inferred← citeshttps://doi.org/10.1016/j.freeradbiomed.2015.02.027openalex-snapshot
The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines
inferred← citeshttps://doi.org/10.1016/j.freeradbiomed.2022.11.023openalex-snapshot
Proteomics revealed the crosstalk between copper stress and cuproptosis, and explored the feasibility of curcumin as anticancer copper ionophore
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e31409openalex-snapshot
Comparison of 177Lu-octreotate and 177Lu-octreotide for treatment in human neuroblastoma-bearing mice
inferred← citeshttps://doi.org/10.1016/j.humpath.2017.04.022openalex-snapshot
A novel fusion of HNRNPA1 – ALK in inflammatory myofibroblastic tumor of urinary bladder
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2018.06.192openalex-snapshot
Selective mechanisms and molecular design of 2,4 Diarylaminopyrimidines as ALK inhibitors
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2025.146212openalex-snapshot
Prediction of potential drug-resistant ALK mutations against fourth-generation inhibitors NVL-655 and TPX-0131
inferred← citeshttps://doi.org/10.1016/j.jcyt.2022.10.007openalex-snapshot
Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells
inferred← citeshttps://doi.org/10.1016/j.jlb.2024.100164openalex-snapshot
Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience
inferred← citeshttps://doi.org/10.1016/j.jmb.2021.167158openalex-snapshot
BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cells
inferred← citeshttps://doi.org/10.1016/j.jmb.2021.167282openalex-snapshot
In vivo Profiling of the Alk Proximitome in the Developing Drosophila Brain
inferred← citeshttps://doi.org/10.1016/j.jmb.2021.167283openalex-snapshot
Mapping the Phospho-dependent ALK Interactome to Identify Novel Components in ALK Signaling
inferred← citeshttps://doi.org/10.1016/j.jmgm.2017.06.010openalex-snapshot
F1174V mutation alters the ALK active conformation in response to Crizotinib in NSCLC: Insight from molecular simulations
inferred← citeshttps://doi.org/10.1016/j.jmoldx.2019.10.015openalex-snapshot
Junction Location Identifier (JuLI)
inferred← citeshttps://doi.org/10.1016/j.jncc.2021.07.005openalex-snapshot
Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group
inferred← citeshttps://doi.org/10.1016/j.jtho.2019.03.007openalex-snapshot
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study
inferred← citeshttps://doi.org/10.1016/j.jtho.2019.11.011openalex-snapshot
Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma
inferred← citeshttps://doi.org/10.1016/j.jtocrr.2020.100112openalex-snapshot
A Novel LINC00478/LINC01549 Intergenic Region-ALK Fusion Responded Well to Alectinib in a Patient With Lung Adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.jtocrr.2025.100934openalex-snapshot
ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report
inferred← citeshttps://doi.org/10.1016/j.lungcan.2016.07.002openalex-snapshot
Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity
inferred← citeshttps://doi.org/10.1016/j.lungcan.2017.10.011openalex-snapshot
GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors
inferred← citeshttps://doi.org/10.1016/j.lungcan.2020.05.014openalex-snapshot
Novel PNPT1-ALK fusion variant exerted significant benefit to crizotinib in NSCLC
inferred← citeshttps://doi.org/10.1016/j.lungcan.2021.02.008openalex-snapshot
Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib
inferred← citeshttps://doi.org/10.1016/j.modpat.2025.100752openalex-snapshot
Pan-Cancer Molecular Biomarkers: Practical Considerations for the Surgical Pathologist
inferred← citeshttps://doi.org/10.1016/j.molcel.2016.06.017openalex-snapshot
CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations
inferred← citeshttps://doi.org/10.1016/j.molmed.2016.11.002openalex-snapshot
Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders
inferred← citeshttps://doi.org/10.1016/j.molonc.2015.11.007openalex-snapshot
EMT is associated with, but does not drive resistance to ALK inhibitors among EML4‐ALK non‐small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.molstruc.2025.142985openalex-snapshot
Allosteric inhibitors for the treatment of cancers (2021-): A review from medicinal chemistry perspectives
inferred← citeshttps://doi.org/10.1016/j.mtnano.2026.100941openalex-snapshot
Nanodrug-mediated strategies for targeting the undruggable: Comparative perspectives on targeted protein degradation and stabilization
inferred← citeshttps://doi.org/10.1016/j.neuropharm.2016.03.003openalex-snapshot
Dependence-induced ethanol drinking and GABA neurotransmission are altered in Alk deficient mice
inferred← citeshttps://doi.org/10.1016/j.oncohp.2014.01.004openalex-snapshot
Actualités pharmacologiques – le crizotinib (Xalkori®)
inferred← citeshttps://doi.org/10.1016/j.pathol.2016.12.345openalex-snapshot
Update on molecular findings in rhabdomyosarcoma
inferred← citeshttps://doi.org/10.1016/j.prp.2020.153286openalex-snapshot
ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma
inferred← citeshttps://doi.org/10.1016/j.prp.2025.155814openalex-snapshot
Renal cell carcinoma with ALK-TPM3 gene fusion and ALK amplification: A case report and literature review
inferred← citeshttps://doi.org/10.1016/j.rmcr.2022.101656openalex-snapshot
Common Presentation of Uncommon Disease: Inflammatory myofibroblastic tumor of the lung, case report
inferred← citeshttps://doi.org/10.1016/j.semcancer.2019.03.006openalex-snapshot
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
inferred← citeshttps://doi.org/10.1016/j.semcancer.2021.06.008openalex-snapshot
Precision medicine in pediatric solid cancers
inferred← citeshttps://doi.org/10.1016/j.semcancer.2022.07.001openalex-snapshot
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
inferred← citeshttps://doi.org/10.1016/j.semdp.2025.150947openalex-snapshot
The expanding family of ALK-rearranged Mesenchymal Neoplasms
inferred← citeshttps://doi.org/10.1016/j.taap.2019.114781openalex-snapshot
A novel ALK inhibitor ZYY inhibits Karpas299 cell growth in vitro and in a mouse xenograft model and induces protective autophagy
inferred← citeshttps://doi.org/10.1016/j.urolonc.2021.04.041openalex-snapshot
“Collecting duct carcinoma of the kidney: diagnosis and implications for management”
inferred← citeshttps://doi.org/10.1016/j.urolonc.2026.111066openalex-snapshot
Beyond clear cell: Rare histologic and molecular variants of renal cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.xcrp.2023.101599openalex-snapshot
LIMS-Kinase provides sensitive and generalizable label-free in vitro measurement of kinase activity using mass spectrometry
inferred← citeshttps://doi.org/10.1016/j.xjidi.2022.100122openalex-snapshot
Sequencing of Cutaneous Squamous Cell Carcinoma Primary Tumors and Patient-Matched Metastases Reveals ALK as a Potential Driver in Metastases and Low Mutational Concordance in Immunocompromised Patients
inferred← citeshttps://doi.org/10.1016/j.yexmp.2018.11.008openalex-snapshot
Molecular and cellular genetics of non-Hodgkin lymphoma: Diagnostic and prognostic implications
inferred← citeshttps://doi.org/10.1016/j.ygeno.2020.10.001openalex-snapshot
Discovery and in silico evaluation of aminoarylbenzosuberene molecules as novel checkpoint kinase 1 inhibitor determinants
inferred← citeshttps://doi.org/10.1016/j.ygeno.2022.110401openalex-snapshot
Genetic determinants of lung cancer: Understanding the oncogenic potential of somatic missense mutations
inferred← citeshttps://doi.org/10.1016/s0007-4551(25)00161-4openalex-snapshot
Réarrangement de ALK dans le cancer pulmonaire non à petites cellules
inferred← citeshttps://doi.org/10.1016/s0140-6736(17)30565-2openalex-snapshot
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
inferred← citeshttps://doi.org/10.1016/s1470-2045(16)30392-8openalex-snapshot
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
inferred← citeshttps://doi.org/10.1016/s1877-1203(17)30053-8openalex-snapshot
Altérations moléculaires anciennes et émergentes : quand les rechercher ?
inferred← citeshttps://doi.org/10.1016/s1877-1203(18)30016-8openalex-snapshot
Classification histomoléculaire des cancers pulmonaires
inferred← citeshttps://doi.org/10.1016/s2213-2600(19)30053-0openalex-snapshot
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
inferred← citeshttps://doi.org/10.1017/9781009336123openalex-snapshot
Targeting Oncogenic Driver Mutations in Lung Cancer
inferred← citeshttps://doi.org/10.1017/9781107707504.006openalex-snapshot
Molecular genetics of soft tissue tumors
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c00722openalex-snapshot
Synthesis and Preclinical Evaluation of [Methylpiperazine-11C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5c01858openalex-snapshot
Crizotinib- or Ceritinib-Conjugated Platinum(IV) Prodrugs As Potent Multiaction Agents Inducing Antiproliferative Effects in 2D and 3D Cancer Cell Models
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.6b00106openalex-snapshot
Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.7b01039openalex-snapshot
Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.9b00446openalex-snapshot
Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.8b00059openalex-snapshot
Exosomes from Irradiated Nonsmall Cell Lung Cancer Cells Reduced Sensitivity of Recipient Cells to Anaplastic Lymphoma Kinase Inhibitors
inferred← citeshttps://doi.org/10.1021/acsabm.5c00771openalex-snapshot
Heparanase-Inhibiting Polymeric Heparan Sulfate Mimetic Attenuates Myeloma Tumor Growth and Bone Metastasis
inferred← citeshttps://doi.org/10.1021/acsami.2c18020openalex-snapshot
Crizotinib Nanomicelles Synergize with Chemotherapy through Inducing Proteasomal Degradation of Mutp53 Proteins
inferred← citeshttps://doi.org/10.1021/acsmedchemlett.9b00378openalex-snapshot
Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer
inferred← citeshttps://doi.org/10.1021/jm500178ropenalex-snapshot
Novel Anaplastic Lymphoma Kinase Inhibitors Targeting Clinically Acquired Resistance
inferred← citeshttps://doi.org/10.1038/bcj.2015.35openalex-snapshot
NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair
inferred← citeshttps://doi.org/10.1038/bcj.2016.52openalex-snapshot
Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene
inferred← citeshttps://doi.org/10.1038/leu.2014.166openalex-snapshot
Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)–anaplastic lymphoma kinase (ALK) acute myeloid leukemia
showing the first 200 of 630 · page through all 630
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.